广东溢多利生物科技股份有限公司 2023 年第一季度报告 债券代码：123018 债券简称：溢利转债 股票代码：300381 股票简称：溢多利 公告编号：2023-018 广东溢多利生物科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 广东溢多利生物科技股份有限公司 2023 年第一季度报告 公司报告期末至季度报告披露日股本是否因发行新股、增发、配股、股权激励行权、回购等原因发生变化且影响所有者 权益金额 是 □否 | | 本报告期 | | | --- | --- | --- | | 支付的优先股股利（元） | | 0.00 | | 支付的永续债利息（元） | | 0.00 | | 用最新股本计算的全面 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,174,006,689.90, a decrease of 37.95% compared to ¥1,892,160,336.27 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥18,232,003.60, representing a significant increase of 115.33% from a loss of ¥118,910,123.08 in 2021[27]. - The basic earnings per share for 2022 was ¥0.0372, recovering from a loss of ¥0.2426 in 2021, marking a 115.33% improvement[27]. - The total assets at the end of 2022 were ¥3,172,143,622.62, down 29.19% from ¥4,479,934,615.27 at the end of 2021[27]. - The company generated operating cash flow of ¥249,773,827.17 in 2022, an increase of 15.14% from ¥216,929,263.66 in 2021[27]. - The company's revenue decreased by 37.95% compared to the same period last year, with a net profit attributable to shareholders of 18.23 million yuan, achieving a turnaround from losses[50]. - Non-recurring gains and losses contributed 108.48 million yuan to the net profit, while the net profit after deducting non-recurring items was approximately a loss of 90.24 million yuan[51]. - The company reported a net profit of 300 million RMB for 2022, with a net profit margin of 25%, up from 22% in the previous year[148]. Investment and Capital Structure - The company reported a significant increase in investment, with a total investment amount of ¥693,035,843.36 for the reporting period, representing a 335.89% increase compared to ¥158,993,022.81 in the previous year[88]. - The company raised a total of RMB 18,958.40 million through the issuance of 11.45 million shares at a price of RMB 27.88 per share, with a net amount of RMB 16,633.56 million after deducting issuance costs[98]. - The company successfully raised RMB 6,250 million from a private placement of 3,081,854 shares at RMB 20.28 per share, resulting in a net amount of RMB 5,650 million after expenses[99]. - The company issued convertible bonds totaling RMB 66,496.77 million, with a net amount of RMB 64,461.42 million after deducting fees[101]. - The company has a total of 1,161 million CNY in financial assets, with a return of 38.79%[92]. - The company has a total share capital of 490,079,795 shares, with 6,430,000 shares repurchased as of December 31, 2022[173]. Business Strategy and Market Position - The company is focused on the development of biological enzyme preparations and animal nutrition and health products, which are closely tied to the seasonal cycles of the aquaculture industry[4]. - The company has a comprehensive strategy for market expansion and product development in the enzyme industry, aiming to enhance its competitive edge[5]. - The company aims to align with the national "14th Five-Year" plan for bio-economy development, targeting a total bio-economy output of ¥22 trillion by 2025[40]. - The company is the largest supplier of feed enzymes in China and aims to maintain its leading position while expanding into international markets[45]. - The company aims to become a benchmark enterprise in the global biological enzyme preparation market and a leader in China's animal nutrition and health industry[44]. - The company plans to expand its product line in the veterinary medicine sector, focusing on steroid hormone products[105]. Research and Development - The company plans to increase R&D investment to enhance its innovation capabilities and solidify its position in the domestic market for biological enzyme preparations[45]. - Research and development expenses increased by 25% to 150 million RMB, reflecting the company's commitment to innovation and new technology[148]. - The company is focusing on optimizing various enzyme strains to enhance product performance and reduce production costs[72]. - The company is committed to developing various new biological products using modern biotechnology[116]. Corporate Governance and Management - The company emphasizes the importance of accurate financial reporting, with all board members present for the approval of the annual report[3]. - The board of directors consists of 7 members, including 3 independent directors, and operates through four specialized committees[131]. - The company has established a complete and independent financial management system, including independent accounting and tax obligations[135]. - The company has a performance evaluation and incentive mechanism in place, linking employee compensation to performance[131]. - The company maintained an independent operational structure, ensuring no interference from the controlling shareholder in business activities[135]. Environmental and Social Responsibility - The company is committed to environmental and social responsibility, integrating these aspects into its business strategy[5]. - In 2022, the company invested approximately 9.5 million yuan in environmental governance and protection, and paid 128,400 yuan in environmental protection tax[194]. - The company actively engages in social responsibility, participating in 11 poverty alleviation and donation projects in various regions[197]. - The company has established an emergency response plan for sudden environmental incidents, which was filed with the local environmental bureau[193]. Employee and Stakeholder Engagement - The total number of employees at the end of the reporting period was 1,148, with 592 in production, 159 in sales, 192 in technology, and 39 in finance[167][168]. - The company has established a performance evaluation system for senior management, linking employee income to work performance to enhance cohesion and attract talent[169]. - The company conducted various training programs to improve employee skills in management, production, R&D, and marketing[170]. - The company has a total of 946.43 million CNY in remuneration for its board and management, reflecting its operational performance and responsibilities[156]. Future Outlook - The company plans to launch two new products in Q2 2023, targeting a market expansion of 10% in the health supplement sector[148]. - The company has set a revenue guidance of 1.5 billion RMB for 2023, which would represent a growth of 25% compared to 2022[148]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 200 million RMB allocated for this purpose[148]. - The company aims to maximize the efficiency of raised funds to meet the working capital needs for business growth[108].

广东溢多利生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 22 日在巨潮资讯网披露了《2022 年年度报告》及其摘要，为便于广大投资者更加 全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 4 月 27 日 （星期四）15:00-17:00 在"价值在线（www.ir-online.cn）"举办 2022 年度业绩 网上说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 会议召开时间：2023 年 4 月 27 日（星期四）15:00-17:00 会议召开方式：网络文字互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 4 月 27 日 前 访 问 网 址 https://eseb.cn/141By6Msx0s 或使用微信扫描下方小程序码进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 的问题进行回答。 | 股票代码：300381 | 股票简称：溢多利 | 公告编号：2023-021 | | --- | --- | --- | | 债券代码：123018 ...

证券代码：300381 证券简称：溢多利 广东溢多利生物科技股份有限公司 投资者关系活动记录表 编号：VTR20160625 | --- | --- | --- | |------------|------------------------|-------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名 | 1. | 汇添富基金管理股份有限公司 林小伟 | | 称及人员姓 | 2. | 华宝兴业基金管理有限公司 窦金虎 | | 名 | 3. | 天弘基金管理有限公司 俞运能 | | | 4. | 联讯证券股份有限公司 王凤华 | | | 5. | 兴业证券股份有限公司 陈娇 张佳博 | | | 6. | 海通证券股份有限公司 张宇 潘莹练 | | | 7. | 国信证券股份有限公司 邓周宇 谢长雁 梁银花 | | ...

证券代码：300381 证券简称：溢多利 广东溢多利生物科技股份有限公司 投资者关系活动记录表 编号：VTR20160603 | --- | --- | --- | |------------|--------------------------|----------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | 活动类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名 | 1. | 东方证券股份有限公司 郭哲 | | 称及人员姓 | 2. | 国泰君安证券股份有限公司 陈宏亮 | | 名 | 3. | 广东新价值投资有限公司 伍梓维 | | 时间 | 2016 年 6 月 3 | 日下午 14:00-16:00 | | 地点 | 珠海市南屏科技园屏北一路 | 8 号 公司 11 楼会议室 | | 上市公司接 | | 常务副总裁、董事会秘书：周德荣 | | 待人员姓名 | | 证券部经理、证券事 ...

证券代码：300381 证券简称：溢多利 广东溢多利生物科技股份有限公司 投资者关系活动记录表 编号：VTR20160511 | --- | --- | --- | |------------|------------|----------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | 活动类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名 | 1. | 平安大华基金管理有限公司 张泽京 乔海英 | | 称及人员姓 | 2. | 鹏华基金管理有限公司 金笑非 段涛 | | 名 | 3. | 景顺长城基金管理有限公司 刘苏 | | | 4. | 华安基金管理有限公司 赵钦 | | | 5. | 国联安基金管理有限公司 焦阳 | | | 6. | 创金合信基金管理有限公司 皮劲松 | | | 7. | 金鹰基金管理有限公司 潘李剑 | | | 8. | 华润元大基金管理有限公司 张磊 ...

证券代码：300381 证券简称：溢多利 广东溢多利生物科技股份有限公司 投资者关系活动记录表 编号：VTR20161109 | --- | --- | --- | |------------|-------------------------|------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | 活动类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | 1. | 海通证券股份有限公司 王鸣阳 | | | 2. | 深圳菁英时代基金管理股份有限公司 曹阳 | | 参与单位名 | 3. | 珠海德瑞恒泰投资基金管理有限公司 李广 李聪 | | 称及人员姓 | 4. | 深圳龙腾资产管理有限公司 于龙 | | 名 | 5. | 深圳市明曜投资管理有限公司 许耀刚 | | | 6. | 珠海亨和资产管理有限公司 田智芳 叶美其 梁博源 郭伟成 | | | ...

股票代码：300381 股票简称：溢多利 债券代码：123018 债券简称：溢利转债 广东溢多利生物科技股份有限公司 投资者关系活动记录表 编号：VTR20200612001 | --- | --- | --- | |------------|------------------------|------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | √ | 其他（参加由广东上市公司协会联合约调研平台举办的医药生 | | | | 物行业上市公司与机构投资者线上交流会） | | 参与单位名 | | 本次线上交流会系由广东上市公司协会联合约调研平台举 | | 称及人员姓 | | 办，通过约调研平台系统完成，会议由平安证券综合研究所医药 | | 名 | | 行业研究员韩盟盟主持，参会人员名单由约调研平台提供，包括 | | | | 中信农业产业基金 ...

股票代码：300381 股票简称：溢多利 债券代码：123018 债券简称：溢利转债 广东溢多利生物科技股份有限公司 投资者关系活动记录表 编号：VTR20200612002 | --- | --- | --- | |------------|----------------------------|-----------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ 其他 | | | 参与单位名 | 太平洋证券：程晓东、王艳君 | | | | 天弘基金：麦骏杰 | | | 称及人员姓 | 长城基金：翁善根 | | | 名 | 沣京资产：李正强 | | | 时间 | 2020 年 6 月 12 | 日下午 14:00-16:00 | | 地点 | 公司总部 | | | 上市公司接 | | 常务副总裁、董事会秘书 周德荣 | | | | 董事长助理、投资发展部总监 刘梦涯 | | --- | -- ...

Company Overview - Guangdong Yiduoli Biotechnology Co., Ltd. is an innovative biotechnology company primarily engaged in the research, production, and sales of biological enzyme preparations, steroid hormone raw materials, and functional feed additives [3][4]. - The company is the first specialized producer of biological enzyme preparations in China and has become the largest manufacturer and service provider in Asia [3][4]. Product Categories - **Biological Enzyme Preparations**: The company has expanded its product range from feed enzymes to energy enzymes, food enzymes, paper-making enzymes, textile enzymes, and environmental enzymes [3][4]. - **Steroid Hormone Raw Materials**: The company has become a significant supplier in the global steroid hormone raw materials industry, focusing on technological innovation in key intermediates [4]. - **Functional Feed Additives**: The company offers alternatives to antibiotic feed additives, leveraging nearly 30 years of experience in the agricultural and animal husbandry sectors [4][5]. Financial Performance - The net profit for the first half of 2020 is expected to increase by 70%-90% compared to the same period last year, with an estimated profit of approximately CNY 66.54 million to CNY 74.37 million [4][5]. - The growth is attributed to increased demand for steroid hormone raw materials due to the COVID-19 pandemic, as well as the implementation of a ban on growth-promoting antibiotics in feed starting July 1, 2020 [4][5]. Market Opportunities - The company aims to capture the growing market for antibiotic alternatives, particularly in light of new regulations prohibiting certain feed additives [4][6]. - The company’s flagship product, a natural plant extract, has been recognized in overseas markets for its effectiveness and is positioned to take advantage of the domestic market following the ban on antibiotic feed additives [6][7]. Future Plans - The company plans to enhance its production capacity for its flagship antibiotic alternative product and expand its market presence [6][7]. - It aims to strengthen its position in the biological enzyme market by increasing production capacity and diversifying its product offerings [7][8].